Sleep parameters and health-related quality of life with bazedoxifene/conjugated estrogens: A randomized trial

Menopause

Volumn 21, Issue 3, 2014, Pages 252-259

  Pinkerton, Joann V ^a   Pan, Kaijie ^b   Abraham, Lucy ^c   Racketa, Jill ^b   Ryan, Kelly A ^b   Chines, Arkadi A ^b   Mirkin, Sebastian ^b  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

^b PFIZER INC   (United States)

^c PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

Author keywords

Bazedoxifene conjugated estrogens; Menopause Specific Quality of Life questionnaire; Quality of life; Sleep

Indexed keywords

BAZEDOXIFENE PLUS CONJUGATED ESTROGEN; CONJUGATED ESTROGEN PLUS MEDROXYPROGESTERONE ACETATE; PLACEBO;

ADULT; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MIDDLE AGED; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; POSTMENOPAUSE; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SLEEP DISORDER; SLEEP PARAMETERS; TREATMENT OUTCOME; VASOMOTOR DISORDER;

DOUBLE-BLIND METHOD; ESTROGENS, CONJUGATED (USP); FEMALE; HEALTH STATUS; HOT FLASHES; HUMANS; INDOLES; MEDROXYPROGESTERONE ACETATE; MIDDLE AGED; PLACEBOS; POSTMENOPAUSE; QUALITY OF LIFE; QUESTIONNAIRES; SLEEP; SLEEP DISORDERS;

EID: 84896703766     PISSN: 10723714     EISSN: 15300374     Source Type: Journal    
DOI: 10.1097/GME.0b013e31829f0433     Document Type: Article

References (34)

1. Lewis V. Undertreatment of menopausal symptoms and novel options for comprehensive management. Curr Med Res Opin 2009;25:2689-2698.
2. Levine JP. Treating menopausal symptoms with a tissue-selective estrogen complex. Gender Med 2011;8:57-68.
3. Ameratunga D, Goldin J, Hickey M. Sleep disturbance in menopause. Intern Med J 2012;42:742-747.
4. Utian WH. Quality of life (QOL) in menopause. Maturitas 2007;57: 100-102.
5. Hess R, Thurston RC, Hays RD, et al. The impact of menopause on health-related quality of life: results from the STRIDE longitudinal study. Qual Life Res 2012;21:535-544.
6. Bolge SC, Balkrishnan R, Kannan H, Seal B, Drake CL. Burden associated with chronic sleep maintenance insomnia characterized by nighttime awakenings among women with menopausal symptoms. Menopause 2010;17:80-86.
7. Acquadro C, Berzon R, Dubois D, et al. Incorporating the patient's perspective into drug development and communication: an ad hoc task force report of the Patient-Reported Outcomes (PRO) Harmonization Group meeting at the Food and Drug Administration, February 16, 2001. Value Health 2003;6:522-531.
8. Utian WH. Psychosocial and socioeconomic burden of vasomotor symptoms in menopause: a comprehensive review. Health Qual Life Outcomes 2005;3:47.
9. Williams RE, Levine KB, Kalilani L, Lewis J, Clark RV. Menopausespecific questionnaire assessment in US populationYbased study shows negative impact on health-related quality of life. Maturitas 2009;62: 153-159.
10. Erlik Y, Tataryn IV, Meldrum DR, Lomax P, Bajorek JG, Judd HL. Association of waking episodes with menopausal hot flushes. JAMA 1981;245:1741-1744.
11. Ohayon MM. Severe hot flashes are associated with chronic insomnia. Arch Intern Med 2006;166:1262-1268.
12. Pinkerton JV, Stovall DW, Kightlinger RS. Advances in the treatment of menopausal symptoms. Womens Health 2009;5:361-384.
13. The North American Menopause Society. Estrogen and progestogen use in postmenopausal women: 2010 position statement of The North American Menopause Society. Menopause 2010;17:242-255.
14. Hays J, Ockene JK, Brunner RL, et al. Effects of estrogen plus progestin on health-related quality of life. N Engl J Med 2003;348: 1839-1854.
15. Brunner RL, Gass M, Aragaki A, et al. Effects of conjugated equine estrogen on health-related quality of life in postmenopausal women with hysterectomy: results from the Women's Health Initiative randomized clinical trial. Arch Intern Med 2005;165:1976-1986.
16. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-333.
17. Anderson GL, Chlebowski RT, Rossouw JE, et al. Prior hormone therapy and breast cancer risk in the Women's Health Initiative randomized trial of estrogen plus progestin. Maturitas 2006;55:103-115.
18. Anderson GL, Limacher M, Assaf AR, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 2004;291: 1701-1712.
19. Barnabei VM, Cochrane BB, Aragaki AK, et al. Menopausal symptoms and treatment-related effects of estrogen and progestin in the Women's Health Initiative. Obstet Gynecol 2005;105:1063-1073.
20. Abraham L, Arbuckle R, Debberstein L, et al. How do breast pain and breakthrough bleeding associated with hormonal treatments for menopausal symptoms impact postmenopausal women's lives: qualitative interviews with postmenopausal women in the USA, China, Mexico, and Italy [Abstract P-19]. Menopause 2011;18:1354.
21. Komm BS. A new approach to menopausal therapy: the tissue selective estrogen complex. Reprod Sci 2008;15:984-992.
22. Lobo RA, Pinkerton JV, Gass ML, et al. Evaluation of bazedoxifene/ conjugated estrogens for the treatment of menopausal symptoms and effects on metabolic parameters and overall safety profile. Fertil Steril 2009;92:1025-1038.
23. Pinkerton JV, Utian WH, Constantine GD, Olivier S, Pickar JH. Relief of vasomotor symptoms with the tissue-selective estrogen complex containing bazedoxifene/conjugated estrogens: a randomized, controlled trial. Menopause 2009;16:1116-1124.
24. Kagan R, Williams RS, Pan K, Mirkin S, Pickar JH. A randomized, placebo- and active-controlled trial of bazedoxifene/conjugated estrogens for treatment of moderate to severe vulvar/vaginal atrophy in postmenopausal women. Menopause 2010;17:281-289.
25. Archer DF, Lewis V, Carr BR, Olivier S, Pickar JH. Bazedoxifene/ conjugated estrogens (BZA/CE): incidence of uterine bleeding in postmenopausal women. Fertil Steril 2009;92:1039-1044.
26. Pickar JH, Yeh I-T, Bachmann G, Speroff L. Endometrial effects of a tissue selective estrogen complex containing bazedoxifene/conjugated estrogens as a menopausal therapy. Fertil Steril 2009;92:1018-1024.
27. Lindsay R, Gallagher JC, Kagan R, Pickar JH, Constantine G. Efficacy of tissue-selective estrogen complex of bazedoxifene/conjugated estrogens for osteoporosis prevention in at-risk postmenopausal women. Fertil Steril 2009;92:1045-1052.
28. Pinkerton JV, Taylor H, Pan K, Chines A, Mirkin S. Breast parameters with bazedoxifene/conjugated estrogens in randomized, controlled trials of postmenopausal women [Abstract S-21]. Menopause 2010; 17:1221-1222.
29. Utian W, Yu H, Bobula J, Mirkin S, Olivier S, Pickar JH. Bazedoxifene/conjugated estrogens and quality of life in postmenopausal women. Maturitas 2009;63:329-335.
30. Bachmann G, Bobula J, Mirkin S. Effects of bazedoxifene/conjugated estrogens on quality of life in postmenopausal women with symptoms of vulvar/vaginal atrophy. Climacteric 2010;13:132-140.
31. Hays RD, Martin SA, Sesti AM, Spritzer KL. Psychometric properties of the Medical Outcomes Study sleep measure. Sleep Med 2005; 6:41-44.
32. Spritzer KL, Hays RD. MOS Sleep Scale: A Manual for Use and Scoring, Version 1.0. Los Angeles, CA: RAND; 2003.
33. Hilditch JR, Lewis J, Peter A, et al. A Menopause-Specific Quality of Life questionnaire: development and psychometric properties. Maturitas 1996;24:161-175.
34. Racketa J, Pinkerton JV, Bushmakin AG, Cappelleri JC, Chines AA, Mirkin S. Direct and indirect effects of bazedoxifene/conjugated estrogens on sleep disturbance. Climacteric 2011;14:82.